{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:47:03Z","timestamp":1791316023380,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7087","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2006,4,20]]},"DOI":"10.1038\/nature04648","type":"journal-article","created":{"date-parts":[[2006,4,19]],"date-time":"2006-04-19T13:15:08Z","timestamp":1145452508000},"page":"1073-1077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":745,"title":["Pharmaco-metabonomic phenotyping and personalized drug treatment"],"prefix":"10.1038","volume":"440","author":[{"given":"T.","family":"Andrew Clayton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Lindon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Antti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Charuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Hanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Provost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Lo\u00efc","family":"Le Net","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind J.","family":"Walley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy K.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,4,1]]},"reference":[{"key":"BFnature04648_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S1471-4914(01)01986-4","volume":"7","author":"BB Spear","year":"2001","unstructured":"Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201\u2013204 (2001)","journal-title":"Trends Mol. Med."},{"key":"BFnature04648_CR2","first-page":"101","volume":"4","author":"V Pagliarulo","year":"2002","unstructured":"Pagliarulo, V., Datar, R. H. & Cole, R. J. Role of genetic and expression profiling in pharmacogenomics: the changing face of patient management. Curr. Issues Mol. Biol. 4, 101\u2013110 (2002)","journal-title":"Curr. Issues Mol. Biol."},{"key":"BFnature04648_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0378-4274(01)00278-8","volume":"120","author":"M Ingelman-Sundberg","year":"2001","unstructured":"Ingelman-Sundberg, M. Genetic variability in susceptibility and response to toxicants. Toxicol. Lett. 120, 259\u2013268 (2001)","journal-title":"Toxicol. Lett."},{"key":"BFnature04648_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00129785-200303060-00002","volume":"3","author":"DW Nebert","year":"2003","unstructured":"Nebert, D. W., Jorge-Nebert, L. & Vesell, E. S. Pharmacogenomics and \u201cindividualized drug therapy\u201d: high expectations and disappointing achievements. Am. J. Pharmacogenomics 3, 361\u2013370 (2003)","journal-title":"Am. J. Pharmacogenomics"},{"key":"BFnature04648_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2165\/00129785-200303030-00001","volume":"3","author":"J van Aken","year":"2003","unstructured":"van Aken, J., Schmedders, M., Feuerstein, G. & Kollek, R. Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am. J. Pharmacogenomics 3, 149\u2013155 (2003)","journal-title":"Am. J. Pharmacogenomics"},{"key":"BFnature04648_CR6","volume-title":"Pharmacology","author":"HP Rang","year":"1995","unstructured":"Rang, H. P., Dale, M. M. & Ritter, J. M. Pharmacology (Churchill Livingstone, Edinburgh, 1995)"},{"key":"BFnature04648_CR7","volume-title":"Normal Microflora: An Introduction to Microbes Inhabiting the Human Body","author":"GW Tannock","year":"1995","unstructured":"Tannock, G. W. Normal Microflora: An Introduction to Microbes Inhabiting the Human Body (Chapman and Hall, London, 1995)"},{"key":"BFnature04648_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/004982599238047","volume":"29","author":"JK Nicholson","year":"1999","unstructured":"Nicholson, J. K., Lindon, J. C. & Holmes, E. \u2018Metabonomics\u2019: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR data. Xenobiotica 29, 1181\u20131189 (1999)","journal-title":"Xenobiotica"},{"key":"BFnature04648_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/1099-0534(2000)12:5<289::AID-CMR3>3.0.CO;2-W","volume":"12","author":"JC Lindon","year":"2000","unstructured":"Lindon, J. C., Nicholson, J. K., Holmes, E. & Everett, J. R. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids combined with pattern recognition. Concepts Magn. Reson. 12, 289\u2013320 (2000)","journal-title":"Concepts Magn. Reson."},{"key":"BFnature04648_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrd728","volume":"1","author":"JK Nicholson","year":"2002","unstructured":"Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov. 1, 153\u2013161 (2002)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature04648_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrd1157","volume":"2","author":"JK Nicholson","year":"2003","unstructured":"Nicholson, J. K. & Wilson, I. D. Understanding \u2018global\u2019 systems biology: metabonomics and the continuum of metabolism. Nature Rev. Drug Discov. 2, 668\u2013676 (2003)","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnature04648_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2217\/14622416.6.7.691","volume":"6","author":"JC Lindon","year":"2005","unstructured":"Lindon, J. C. et al. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6, 691\u2013699 (2005)","journal-title":"Pharmacogenomics"},{"key":"BFnature04648_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/1568026023394498","volume":"2","author":"JP Shockcor","year":"2002","unstructured":"Shockcor, J. P. & Holmes, E. Metabonomic applications in toxicity screening and disease diagnosis. Curr. Top. Med. Chem. 2, 35\u201351 (2002)","journal-title":"Curr. Top. Med. Chem."},{"key":"BFnature04648_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1365-201x.2002.00924.x","volume":"174","author":"ES Rawson","year":"2002","unstructured":"Rawson, E. S., Clarkson, P. M., Price, T. B. & Miles, M. P. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. Acta Physiol. Scand. 174, 57\u201365 (2002)","journal-title":"Acta Physiol. Scand."},{"key":"BFnature04648_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0009-8981(97)00110-1","volume":"265","author":"C Zuppi","year":"1997","unstructured":"Zuppi, C. et al. 1H NMR spectra of normal urines: reference ranges of the major metabolites. Clin. Chim. Acta 265, 85\u201397 (1997)","journal-title":"Clin. Chim. Acta"},{"key":"BFnature04648_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1023\/A:1007492202045","volume":"14","author":"R Zoratti","year":"1998","unstructured":"Zoratti, R. A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur. J. Epidemiol. 14, 9\u201321 (1998)","journal-title":"Eur. J. Epidemiol."},{"key":"BFnature04648_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jpba.2004.08.002","volume":"36","author":"EM Lenz","year":"2004","unstructured":"Lenz, E. M. et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal. 36, 841\u2013849 (2004)","journal-title":"J. Pharm. Biomed. Anal."},{"key":"BFnature04648_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0300-483X(93)90132-C","volume":"77","author":"CJ Waterfield","year":"1993","unstructured":"Waterfield, C. J., Turton, J. A., Scales, M. D. C. & Timbrell, J. A. The correlation between urinary and liver taurine levels and between pre-dose urinary taurine and liver damage. Toxicology 77, 1\u20135 (1993)","journal-title":"Toxicology"},{"key":"BFnature04648_CR19","doi-asserted-by":"publisher","first-page":"G1274","DOI":"10.1152\/ajpgi.2001.280.6.G1274","volume":"280","author":"E Waters","year":"2001","unstructured":"Waters, E. et al. Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G1274\u2013G1279 (2001)","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"BFnature04648_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0306-3623(94)00203-Y","volume":"26","author":"JA Timbrell","year":"1995","unstructured":"Timbrell, J. A., Seabra, V. & Waterfield, C. J. The in vivo and in vitro protective properties of taurine. Gen. Pharmacol. 26, 453\u2013462 (1995)","journal-title":"Gen. Pharmacol."},{"key":"BFnature04648_CR21","first-page":"473","volume-title":"Textbook of Biochemistry with Clinical Correlations","author":"MW Coomes","year":"1997","unstructured":"Coomes, M. W. in Textbook of Biochemistry with Clinical Correlations (ed. Devlin, T. M.) 473\u2013474 (Wiley-Liss, New York, 1997)"},{"key":"BFnature04648_CR22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1006\/taap.1996.0151","volume":"139","author":"L Liu","year":"1996","unstructured":"Liu, L. & Klaassen, C. D. Different mechanisms of saturation of acetaminophen sulfate conjugation in mice and rats. Toxicol. Appl. Pharmacol 139, 128\u2013134 (1996)","journal-title":"Toxicol. Appl. Pharmacol"},{"key":"BFnature04648_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1006\/taap.1994.1076","volume":"125","author":"JL Smith","year":"1994","unstructured":"Smith, J. L., Wishnok, J. S. & Deen, W. M. Metabolism and excretion of methylamines in rats. Toxicol. Appl. Pharmacol. 125, 296\u2013308 (1994)","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"BFnature04648_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1021\/tx0340293","volume":"16","author":"AW Nicholls","year":"2003","unstructured":"Nicholls, A. W., Mortishire-Smith, R. J. & Nicholson, J. K. NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem. Res. Toxicol. 16, 1395\u20131404 (2003)","journal-title":"Chem. Res. Toxicol."},{"key":"BFnature04648_CR25","doi-asserted-by":"publisher","first-page":"S788","DOI":"10.1111\/j.1365-2125.2004.02297.x","volume":"58","author":"DM Grant","year":"2004","unstructured":"Grant, D. M., Tang, B. K. & Kalow, W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol. 58, S788\u2013S793 (2004)","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnature04648_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1021\/ac048803i","volume":"77","author":"O Cloarec","year":"2005","unstructured":"Cloarec, O. et al. Evaluation of the O-PLS limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal. Chem. 77, 517\u2013526 (2005)","journal-title":"Anal. Chem."},{"key":"BFnature04648_CR27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1021\/ac048630x","volume":"77","author":"O Cloarec","year":"2005","unstructured":"Cloarec, O. et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal. Chem. 77, 1282\u20131289 (2005)","journal-title":"Anal. Chem."},{"key":"BFnature04648_CR28","unstructured":"Claridge, T. D. W. (ed.) High-Resolution NMR Techniques in Organic Chemistry. Tetrahedron Organic Chemistry Series 19 (Elsevier, Amsterdam, 1999)"},{"key":"BFnature04648_CR29","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/clinchem\/30.10.1631","volume":"30","author":"JR Bales","year":"1984","unstructured":"Bales, J. R., Sadler, P. J., Nicholson, J. K. & Timbrell, J. A. Urinary excretion of acetaminophen and its metabolites as studied by proton NMR spectroscopy. Clin. Chem. 30, 1631\u20131636 (1984)","journal-title":"Clin. Chem."},{"key":"BFnature04648_CR30","first-page":"91","volume":"244","author":"Z Gregus","year":"1988","unstructured":"Gregus, Z., Madhu, C. & Klaassen, C. D. Species variation in toxication and detoxication of acetaminophen in vivo: a comparative study of biliary and urinary excretion of acetaminophen metabolites. J. Pharmacol. Exp. Ther. 244, 91\u201399 (1988)","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature04648","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature04648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature04648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T05:03:17Z","timestamp":1646197397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature04648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":30,"journal-issue":{"issue":"7087","published-print":{"date-parts":[[2006,4,20]]}},"alternative-id":["BFnature04648"],"URL":"https:\/\/doi.org\/10.1038\/nature04648","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13779.373100","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.13779.471276","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.13779.793476752","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]},"assertion":[{"value":"17 October 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors J.R.E., R.J.W., D.B., C.C., G.H. and J.-L.L.N. are employees of Pfizer. Authors J.K.N. and J.C.L. have interests in Metabometrix in addition to holding academic posts at Imperial College London. Authors T.A.C. and O.C. are employees of Imperial College London with T.A.C. funded by Pfizer. H.A. holds an academic post at the University of Ume\u00e5, Sweden. In addition, T.A.C., J.R.E., J.C.L. and J.K.N. are named as inventors on patent applications relating to pharmaco-metabonomic technologies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}